To understand who really controls CureVac NV (NASDAQ:CVAC), it’s important to understand the business’s ownership structure. We can see that a private equity firm owns most of the company with his 38% ownership. In other words, the group stands to gain the most if the share price rises (or suffer the most loss if it falls).
Clearly, private equity firms have benefited the most after their market capitalization rose by US$71 million last week.
The chart below expands on CureVac’s various ownership groups.
See our latest analysis on CureVac
What does institutional ownership tell you about CureVac?
Because institutional investors typically measure themselves against benchmarks when reporting to their investors, they are often more enthusiastic about a stock when it is included in a major index. Most companies are expected to have several institutions registered, especially if they are growing.
You can see that CureVac has institutional investors. They own a significant portion of the company’s stock. This may indicate that the company has some credibility in the investment community. However, caution should be exercised in relying on the validation that institutional investors assume. They get it wrong sometimes too. When two large institutional investors try to sell their shares at the same time, it’s not uncommon for the stock price to drop significantly. As such, it’s worth taking a look at CureVac’s historical earnings trajectory (below). Of course, keep in mind that there are other factors to consider as well.
Hedge funds don’t have a lot of stock in CureVac. dievini Hopp BioTech Holding GmbH & Co. KG is now the company’s largest shareholder with his 38% of outstanding shares. Meanwhile, the second and third largest shareholders hold 16% of the outstanding shares and his 8.0% respectively.
Further investigation revealed that the top two shareholders jointly controlled more than half of the company’s shares. This means that you have considerable power to influence company decisions.
Researching institutional ownership of companies can add value to your research, but it’s also a good idea to research analyst recommendations to get a better understanding of the stock’s expected performance. . There are many analysts covering stocks, so it might be worth taking a look at their forecasts as well.
CureVac Insider Ownership
While the precise definition of an insider can be subjective, we believe that most directors are insiders. Management should be responsive to the board, and the board should represent the interests of the shareholders. In particular, top-level managers may be on the board of directors.
Most people view insider ownership positively because it can indicate that the board works well with other shareholders. However, in some cases, this group may be overly privileged.
You can report that an insider owns shares of CureVac NV. This is a big company, so it’s good to see this level of collaboration. The insider said at current prices he owns shares worth US$134 million. Good to see this level of investment by insiders. You can check if an Insider has made a recent purchase here.
general public
The general public, usually private investors, own 25% of CureVac. This group does not decide everything, but it definitely has a big influence on the management of the company.
Private equity ownership
With 38% ownership, the private equity firm is well positioned to play a role in shaping corporate strategy focused on value creation. Some may like this because private equity can be an activist to hold management accountable. But sometimes private equity is sold and the company goes public.
public company ownership
A public company appears to own 8.0% of CureVac. This may be of strategic interest and the two companies may have related business interests. They may have broken up. This retention is probably worth further investigation.
Next step:
It’s well worth considering the different groups that own companies, but there are other factors that are even more important.Case in point: we found CureVac One Warning Sign You should know.
If you’re like me, think about whether this company will grow or shrink. Luckily, you can check out this free report that shows analysts’ predictions for the future.
Note: The numbers in this article are calculated using the last 12 months of data. This refers to his 12-month period ending on the last day of the month in which the financial statements are dated. This may not match the annual report figures for the full year.
Valuation is complicated, but we’re here to help make it simple.
find out if cure back You may be overestimated or underestimated by checking out our comprehensive analysis including: Fair value estimates, risks and warnings, dividends, insider trading and financial health.
View Free Analysis
Do you have feedback on this article? What interests you? contact directly with us. Or send an email to our editorial team (at) Simplywallst.com.
This article by Simply Wall St is general in nature. We provide comments based on historical data and analyst projections using only unbiased methodologies and our articles are not intended as financial advice. It is not a recommendation to buy or sell stocks and does not take into account your objectives or financial situation. We aim to deliver long-term focused analysis based on fundamental data. Please note that our analysis may not take into account the latest price-sensitive company announcements or qualitative materials. Is not …
